/
IRMD
$95.56+$1.49 (+1.58%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.2B
13M shares
52-week range
$55.11 – $107.90
77% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$65.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.4M | $38.5M | $31.7M | $41.8M | $53.3M | $65.6M | $73.2M | $83.8M |
| Cost of revenue | $7.2M | $8.8M | $8.1M | $9.8M | $12.0M | $15.4M | $16.9M | $19.5M |
| Gross profit | $23.2M | $29.7M | $23.6M | $32.0M | $41.3M | $50.2M | $56.3M | $64.3M |
| Gross margin | 76.3% | 77.1% | 74.3% | 76.6% | 77.4% | 76.5% | 76.9% | 76.7% |
| R&D | $1.5M | $1.4M | $1.9M | $1.9M | $2.3M | $2.9M | $2.8M | $3.0M |
| Operating income | $6.0M | $8.6M | −$756.1K | $9.8M | $15.6M | $20.0M | $22.0M | $26.1M |
| EBITDA | $7.1M | $9.9M | $582.7K | $11.2M | $16.9M | $22.5M | $25.1M | $30.7M |
| Net income | $6.3M | $9.6M | $1.4M | $9.3M | $12.8M | $17.2M | $19.2M | $22.5M |
| Net margin | 20.7% | 25.0% | 4.3% | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
| EPS (diluted) | 0.52 | 0.78 | 0.11 | 0.74 | 1.02 | 1.35 | 1.50 | 1.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $91M | $2.08 | $1.37–$2.80 | 1 |
| 2027 | $101M | $2.35 | $2.35–$2.36 | 1 |
| 2028 | $113M | $2.70 | $2.69–$2.71 | 1 |
| 2029 | $132M | $3.04 | $3.03–$3.05 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$51.89
Price
$95.56
Implied downside
-46%
Peer comparison
iRadimed Corporation
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
www.iradimed.com- Employees
- 166
- IPO / List date
- Jul 16, 2014
- HQ
- ORLANDO, FL
Held by traders on TradeandTell
No one on the platform currently holds IRMD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 440,712 | $42.4M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 1.12% ($1.07/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-15 | $0.2000 | 2026-05-29 |
| 2026-02-23 | $0.2000 | 2026-03-06 |
| 2025-12-17 | $0.5000 | 2025-12-30 |
| 2025-11-14 | $0.1700 | 2025-11-25 |
| 2025-08-18 | $0.1700 | 2025-08-28 |
| 2025-05-20 | $0.1700 | 2025-05-30 |
| 2025-02-24 | $0.1700 | 2025-03-05 |
| 2024-11-15 | $0.1500 | 2024-11-25 |
| 2024-08-20 | $0.1500 | 2024-08-30 |
| 2024-05-17 | $0.1500 | 2024-05-30 |
Recent trades on TradeandTell
No one on the platform has traded IRMD yet.
